| abstract |
The present invention includes, for example, Lewy bodies and/or Lewy neurites such as Parkinson's disease (PD), but is not limited thereto, alpha-synuclein (α-synuclein, A-synuclein, a-synuclein, a- Synuclein, A-syn, α-syn, aSyn, SNCA, Alzheimer's disease (AD) non-amyloid beta component of amyloid plaques, non-A4 component of amyloid precursors, NACP) diagnosis of disorders and abnormal groups related to aggregates, disease It relates to novel compounds that can be used for monitoring progress or monitoring drug activity. These instant compounds are particularly useful for diagnosing the preclinical condition of such disorders, monitoring residual disorders, or predicting the responsiveness of patients suffering from such disorders and treating them with specific agents. |